Evidence map›Paper›PMID 36499016›Full record

ArticleInternational journal of molecular sciences2022

Different Types of Chronic Inflammation Engender Distinctive Immunosenescent Profiles in Affected Patients.

Eleni Moysidou, Georgios Lioulios, Aliki Xochelli, Vasiliki Nikolaidou, Michalis Christodoulou, Zoi Mitsoglou, Stamatia Stai, Asimina Fylaktou, Aikaterini Papagianni, Maria Stangou

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. New Trends in Pathology: From Cell Morphology to Molecular Medicine.International journal of molecular sciences · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Eleni MoysidouSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thesaloniki, Greece.ORCID 0000-0002-6874-7173
Georgios LiouliosSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thesaloniki, Greece.
Aliki XochelliDepartment of Immunology, National Histocompatibility Center, Hippokration General Hospital, 54642 Thessaloniki, Greece.
Vasiliki NikolaidouDepartment of Immunology, National Histocompatibility Center, Hippokration General Hospital, 54642 Thessaloniki, Greece.
Michalis ChristodoulouSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thesaloniki, Greece.ORCID 0000-0001-9565-6931
Zoi MitsoglouSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thesaloniki, Greece.
Stamatia StaiSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thesaloniki, Greece.
Asimina FylaktouDepartment of Immunology, National Histocompatibility Center, Hippokration General Hospital, 54642 Thessaloniki, Greece.
Aikaterini PapagianniSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thesaloniki, Greece.
Maria StangouSchool of Medicine, Aristotle University of Thessaloniki, 45642 Thesaloniki, Greece.ORCID 0000-0003-2496-9863
Aristotle University of Thessaloniki · GRHippocration General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunosenescence encompasses a spectrum of lymphocyte phenotypic alterations. The aim of the study was to evaluate immunosenescent effect of two different forms of chronic inflammation, Systemic Lupus Erythematosous (SLE), a systemic autoimmune disease, and End-Stage Kidney Disease (ESKD), a chronic inflammatory disorder. Certain lymphocyte surface molecules, including CD31, CD45RA, CCR7, CD28, CD57, for T, and IgD, CD27 for B lymphocytes, were analyzed by flow cytometry in 30 SLE and 53 ESKD patients on hemodialysis (HD), and results were compared to 31 healthy controls (HC) of similar age, gender, and nationality. Significant Lymphopenia was evident in both SLE and ESKD-HD patients, compared to HC, affecting B cells 75.4 (14.4−520.8), 97 (32−341), and 214 (84−576) cells/μL, respectively, p < 0.0001, and CD4 cells 651.2 (71.1−1478.2), 713 (234−1509), and 986 (344−1591) cells/μL, respectively, p < 0.0001. The allocation of B cell subpopulations was remarkably different between SLE and ESKD-HD patients. SLE showed a clear shift to senescence (CD19IgD-CD27−) cells, compared to ESKD-HD and HC, 11.75 (10)% vs. 8 (6) vs. 8.1 (10), respectively. Regarding T lymphocytes, Central Memory CD8 cells predominated in both SLE and ESKD-HD patients compared to HC, 53 (50)%, 52 (63), and 24 (64)%, respectively, while ESKD-HD but not SLE patients also had increased expression of CD4CD28− and CD8CD28− cells. In conclusion, both diseases are followed by significant lymphopenia; however, the senescent phenomenon affects the B lymphocyte compartment in SLE patients and T lymphocytes in ESKD-HD patients.

Indexed as

ImmunosenescenceLupus Erythematosus, SystemicLymphopeniaCD28 AntigensCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFlow CytometryHumansInflammationLeukocyte Common AntigensCD28 AntigensLeukocyte Common Antigensend-stage kidney diseaselymphocytesmemory cellsnaïve cellssenescencesystemic lupus erythematosus

Identifiers

PMID36499016
PMCPMC9735546
OpenAlexW4309934813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.